IRAK1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL232042	1.00	4/20
SCHEMBL147422	0.66	4/20
SCHEMBL144979	0.56	4/20
Linifanib (SCHEMBL93804)	1.00	3/20
SCHEMBL175464	0.82	3/20
SCHEMBL264158	0.79	3/20
SCHEMBL169834	0.68	3/20
SCHEMBL146734	0.67	3/20
SCHEMBL144651	0.67	3/20
SCHEMBL146677	0.67	3/20
SCHEMBL144378	0.66	3/20
SCHEMBL142020	0.65	3/20
SCHEMBL148704	0.62	3/20
SCHEMBL147730	0.61	3/20
SCHEMBL148478	0.61	3/20
SCHEMBL144118	0.61	3/20
SCHEMBL144615	0.61	3/20
SCHEMBL147715	0.61	3/20
SCHEMBL143818	0.61	3/20
SCHEMBL143827	0.59	3/20

Clinical trials — most relevant to IRAK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy and Safety of Ivarmacitinib Monotherapy in the Treatment of csDMARDs-IR Rheumatoid Arthritis	PHASE4	NOT_YET_RECRUITING
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis	PHASE4	NOT_YET_RECRUITING
Clinical Evaluation of the Effect of Metformin in Sepsis	PHASE3	UNKNOWN
Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS)	PHASE2/PHASE3	COMPLETED
IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.	PHASE2	UNKNOWN
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms	PHASE1/PHASE2	RECRUITING
Cilostazol in Parkinson's Disease	PHASE2	NOT_YET_RECRUITING
suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)	PHASE2	COMPLETED
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)	PHASE1/PHASE2	RECRUITING
Colchicine and Inflammation in Hemodialysis Patients	PHASE2	UNKNOWN
The Effects of GLA on Human Volunteers	PHASE1	COMPLETED
Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined	EARLY_PHASE1	RECRUITING
RNA Cloning and Visualization in Human Atherosclerosis	nan	COMPLETED
MicroRNAs and Cytokines in Peri-Implantitis Tissue	nan	UNKNOWN
The Mechanisms and Significances of Synergistic Effects of Mycophenolic Acid and LPS on IL-1β Secretion by Mononuclear	nan	UNKNOWN
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry Bad Cholesterol in the Blood	nan	COMPLETED
The Role of Toll-like Receptor-4 in Periodontitis Patients With End-stage Renal Disease in a Sample of Egyptian Population	nan	RECRUITING
Probiotics and Systemic Inflammation in Patients With Metabolic Syndrome and High Cardiovascular Risk	nan	WITHDRAWN
Toll-like Receptor 2 Gene Polymorphism, Serum Cytokines and Susceptibility to Disease Severity or Treatment Response of Pulmonary Tuberculosis	nan	COMPLETED
Deep Phenotyping of Cutaneous Lupus Erythematosus	nan	UNKNOWN
Activation of a Cutaneous Inflammasome in the Skin of Hidradenitis Suppurativa Patients	nan	COMPLETED
The Value of Interleukin-1β and Interleukin-33 Genetic Expression in the Pathogenesis and Differentiation of Primary ITP and SLE-Related Thrombocytopenia	nan	NOT_YET_RECRUITING
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
Effect of Periodontal Treatment on Inflammasome Proteins in Periodontal Diseases	nan	UNKNOWN
Vitamin D With Omega-3 or Metformin in Osteoarthritis	nan	NOT_YET_RECRUITING
Assessment of Salivary GM-CSF, MIP, and IL-1β Levels in Subjects With Varying Periodontal Conditions	nan	RECRUITING
Clinical Phenotypes in Pericarditis: IL-1RA Antibodies and suPAR Levels	nan	RECRUITING
Novel Biomarkers in Inflammatory Bowel Disease	nan	COMPLETED
Periduroscopy: Correlation Between the Outcome of Procedure and Histological-biochemical, Neuroinflammation and Genetic Factors.	nan	UNKNOWN
Pigeon Peas (Cajanus Cajan) : a Natural Anti-inflammatory Facilitating Weight Loss in Obese Patients Returning to Sport?	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a IRAK1 binder may also engage these)

Protein	Name	Similarity
Q2LGB3	—	1.000	Q2LGB3 →
Q62406	—	0.995	Q62406 →
Q63572	—	0.993	Q63572 →
TESK1	Dual specificity testis-specific protein kinase 1	0.993	landscape →
Q8VDG6	—	0.990	Q8VDG6 →
IRAK2	Interleukin-1 receptor-associated kinase-like 2	0.989	landscape →
Q8R2S1	—	0.989	Q8R2S1 →
Q80XI6	—	0.989	Q80XI6 →
Q8K330	—	0.989	Q8K330 →
Q0P5I2	—	0.988	Q0P5I2 →
SIK1	Serine/threonine-protein kinase SIK1	0.988	landscape →
Q5RA67	—	0.988	Q5RA67 →
Q8CFA1	—	0.988	Q8CFA1 →
Q5R810	—	0.988	Q5R810 →
O70146	—	0.987	O70146 →
Q66HA1	—	0.987	Q66HA1 →
Q9Y6S9	—	0.987	Q9Y6S9 →
O94761	—	0.987	O94761 →
LMTK3	Serine/threonine-protein kinase LMTK3	0.986	landscape →
Q8BLR5	—	0.986	Q8BLR5 →
Q5XIS1	—	0.985	Q5XIS1 →
Q60700	—	0.985	Q60700 →
Q4QQS0	—	0.985	Q4QQS0 →
Q9Z0E3	—	0.985	Q9Z0E3 →
Q811H0	—	0.985	Q811H0 →
O70405	—	0.984	O70405 →
A0A8I3PMN2	—	0.984	A0A8I3PMN2 →
Q7Z6P3	—	0.984	Q7Z6P3 →
Q5XJV6	—	0.984	Q5XJV6 →
Q60670	—	0.984	Q60670 →